-
1 Comment
Burning Rock Biotech Limited is currently in a long term downtrend where the price is trading 7.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 29.7.
Burning Rock Biotech Limited's total revenue rose by 48.5% to $132M since the same quarter in the previous year.
Its net income has dropped by 64.6% to $-156M since the same quarter in the previous year.
Finally, its free cash flow fell by 73.4% to $-166M since the same quarter in the previous year.
Based on the above factors, Burning Rock Biotech Limited gets an overall score of 2/5.
| Exchange | NASDAQ |
|---|---|
| ISIN | US12233L1070 |
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Target Price | 5.54 |
|---|---|
| PE Ratio | None |
| Dividend Yield | 0.0% |
| Beta | 0.2 |
| Market Cap | 302M |
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BNR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
